Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Grade 1-3a: Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2

被引：17

作者：

Kim, Tae Min ^{[1
]}

Taszner, Michal ^{[2
]}

Cho, Seok-Goo ^{[3
]}

Novelli, Silvana ^{[4
]}

Le Gouill, Steven ^{[5
]}

Poon, Michelle Limei ^{[6
]}

Villasboas, Jose C. ^{[7
]}

Champion, Rebecca ^{[8
]}

Bachy, Emmanuel ^{[9
,10
]}

Guidez, Stephanie ^{[11
]}

Alonso, Aranzazu Alonso ^{[12
]}

Jagadeesh, Deepa ^{[13
]}

Merli, Michele ^{[14
]}

Tucker, David ^{[15
]}

Cai, Jingxian ^{[16
]}

De Oliveira, Carolina Leite ^{[16
]}

Zhu, Min ^{[16
]}

Chaudhry, Aafia ^{[16
]}

Mohamed, Hesham ^{[16
]}

Ambati, Srikanth R. ^{[16
]}

Luminari, Stefano ^{[17
]}

机构：

[1] Seoul Natl Univ Hosp, Seoul, South Korea

[2] Uniwersyteckie Ctr Kliniczne Klin Hematol & Trans, Gdansk, Poland

[3] Catholic Univ Korea, Seoul St Marys Hosp Hematol, Seoul, South Korea

[4] Hosp Santa Creu & Sant Pau, Barcelona, Spain

[5] Hosp Grp Inst Curie, Paris, France

[6] Hematol Oncol Natl Univ Hosp, Singapore, Singapore

[7] Mayo Clin, Rochester, NY USA

[8] Norton Canc Inst, Louisville, KY USA

[9] Hosp Civils Lyon, Lyon, France

[10] Univ Claude Bernard Lyon 1, Lyon, France

[11] Ctr Hosp Univ CHU Poitiers, Poitiers, France

[12] Hosp Univ Quiron Salud Madrid, Madrid, Spain

[13] Cleveland Clin, Main Campus, Cleveland, OH 44106 USA

[14] Osped Circolo & Fdn Macchi, Hematol, Varese, Italy

[15] Royal Cornwall Hosp, Truro, Cornwall, England

[16] Regeneron Pharmaceut Inc, Tarrytown, NY USA

[17] Azienda Unita Sanitaria Locale IRCCS, Div Hematol, Reggio Emilia, Italy

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-158404

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：2280 / 2282

页数：3

共 50 条

[21] Trial in Progress: Odronextamab for the Treatment of Patients with Relapsed/Refractory Mantle Cell Lymphoma Following Prior BTK Inhibitor Therapy - a Cohort of the ELM-2 Study
Cho, Seok-Goo
Kim, Tae Min
Taszner, Michal
Chen, Tsai-Yun
Choudhry, Aafia
Ufkin, Melanie
Uppala, Amulya
Sabir, Ayesha
Mohamed, Hesham
Ambati, Srikanth
Bachy, Emmanuel
BLOOD, 2024, 144 : 6302 - 6303
[22] CURRENT EPCORITAMAB PLUS RITUXIMAB AND LENALIDOMIDE (R2) PERCEPTIONS FOR PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)
Levine, E.
Gentile, D.
Swain, R.
Bone, R. N.
Jennings-Zhang, L.
Jeune-Smith, Y.
Feinberg, B.
VALUE IN HEALTH, 2024, 27 (12) : S342 - S342
[23] Efficacy and Safety of Single-Agent Zandelisib Administered By Intermittent Dosing in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Final Results of the Tidal Phase 2 Study
Zelenetz, Andrew D.
Jurczak, Wojciech
Ribrag, Vincent
Linton, Kim M.
Collins, Graham P.
Bishton, Mark
Lopez Jimenez, Javier
Dholaria, Bhagirathbhai
Mengarelli, Andrea
Phillips, Tycel J.
Sungala, Nagendra Prasad
Chan, Henry
Musuraca, Gerardo
Sheehy, Oonagh
Yan, Junyi
Xu, Weiming
Azoulay, Michel
Zinzani, Pier Luigi
BLOOD, 2022, 140 : 3595 - 3597
[24] Clinical Outcomes of Patients With Relapsed/Refractory Follicular Lymphoma (R/R FL) Treated With Tisagenlecleucel: Phase 2 ELARA 3-Year Follow-Up
Schuster, Stephen J.
Fowler, Nathan Hale
Dickinson, Michael
Martinez-Lopez, Joaquin
Kolstad, Arne
Butler, Jason
Ghosh, Monalisa
Popplewell, Leslie
Chavez, Julio C.
Bachy, Emmanuel
Kato, Koji
Harigae, Hideo
Kersten, Marie Jose
Andreadis, Charalambos
Riedell, Peter A.
Ho, P. Joy
Perez-Simon, Jose Antonio
Chen, Andy I.
Nastoupil, Loretta J.
von Tresckow, Bastian
Ferreri, Andres Jose Maria
Teshima, Takanori
Patten, Piers E. M.
McGuirk, Joseph P.
Petzer, Andreas L.
Offner, Fritz
Viardot, Andreas
Zinzani, Pier Luigi
Malladi, Ram
Zia, Aiesha
Awasthi, Rakesh
Paule, Ines
Germano, Davide
Ramos, Roberto
Hsu, Pei
Thieblemont, Catherine
Dreyling, Martin
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S495 - S496
[25] Randomized Phase 2 Zanubrutinib (BGB-3111) + Obinutuzumab Vs Obinutuzumab Monotherapy in Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL)
Fowler, Nathan H.
Trotman, Judith
Auer, Rebecca
Flowers, Christopher R.
Reed, William F.
Ivanova, Elena
Huang, Jane
Zinzani, Pier Luigi
BLOOD, 2019, 134
[26] Polatuzumab vedotin plus obinutuzumab plus venetoclax in patients with relapsed/refractory (R/R) follicular lymphoma (FL): Primary analysis of a phase 1b/2 trial.
Bannerji, Rajat
Yuen, Sam
Phillips, Tycel Jovelle
Arthur, Christopher
Isufi, Iris
Marlton, Paula
Seymour, John Francis
Corradini, Paolo
Molinari, Annalia
Gritti, Giuseppe
Emmons, Robert
Hirata, Jamie
Musick, Lisa
Saha, Sourish
Croft, Brandon
Flowers, Christopher
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[27] Efficacy and safety of zandelisib administered by intermittent dosing (ID) in patients with relapsed or refractory (R/R) follicular lymphoma (FL): Primary analysis of the global phase 2 study TIDAL.
Zelenetz, Andrew David
Jurczak, Wojciech
Ribrag, Vincent
Linton, Kim
Collins, Graham P.
Lopez-Jimenez, Javier
Reddy, Nishitha
Mengarelli, Andrea
Phillips, Tycel Jovelle
Musuraca, Gerardo
Sheehy, Oonagh
Li, Joanne
Xu, Weiming
Azoulay, Michel Meyer
Ghalie, Richard
Zinzani, Pier Luigi
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[28] Health-Related Quality of Life and Symptoms in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Odronextamab Monotherapy in the Phase 2 ELM-2 Study
Iskierka-Jazdzewska, Elzbieta
Kim, Won Seog
Cho, Seok-Goo
Kim, Tae Min
Jarque, Isidro
Robak, Tadeusz
Poon, Michelle
Prince, H. Miles
Yong, Sung
Lim, Francesca
Carpio, Cecilia
Tan, Tran-Der
Ayyappan, Sabarish
Gutierrez, Antonio
Zhang, Huilai
Cao, Junning
Zhang, Mingzhi
Tessoulin, Benoit
Li, Jingjin
Ivanescu, Cristina
BLOOD, 2023, 142
[29] Results of the PI3Kδ inhibitor ME-401 alone or with rituximab in relapsed/refractory (R/R) follicular lymphoma (FL).
Zelenetz, Andrew David
Jagadeesh, Deepa
Reddy, Nishitha M.
Stathis, Anastasios
Salman, Huda S.
Asch, Adam Steven
Kenkre, Vaishalee Padgaonkar
Jhangiani, Haresh S.
Iasonos, Alexia
Soumerai, Jacob D.
Llorin, Judith
Pagel, John M.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[30] Subcutaneous Epcoritamab in Combination with R 2 (Rituximab and Lenalidomide) in Patients with Relapsed or Refractory Follicular Lymphoma: Preliminary Results from a Phase 1/2 Trial
Linton, Kim M.
Wahlin, Bjorn
Leepa, Sirpa
Morschhauser, Franck
Elliot, Brian
Liu, Tracy
Stirner, Mariana Cota
Abbas, Aqeel
Falchi, Lorenzo
BLOOD, 2021, 138

← 1 2 3 4 5 →